OncoSignal
Live from Open Targets Platform, fetched 2026-11-12 00:07 UTC. Every row links to its source record.

CIROZ ciliated left-right organizer protein containing ZP-N domains

ENSG00000175262 · protein coding · Open Targets profile

Plays a role in left-right patterning process. .

In 1 of 7 cancers, the evidence for CIROZ comes mainly from inherited variants

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751Ewing sarcomaEwing sarcomaEwing sarcoma: germline 0.51lung fibrosis-immunodeficiency-46,XX go…lung fibrosis-immunodeficiency-46,XX gonadal dysgenesis syndromegastric cancergastric cancerclear cell renal carcinomaclear cell renal carcinomasarcomasarcomanonpapillary renal cell carcinomanonpapillary renal cell carcinomaovarian serous cystadenocarcinomaovarian serous cystadenocarcinoma

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

No positive tractability buckets.

gnomAD loss of function constraint: o/e 0.7134199738502502 (upper bound 0.9097700119018555). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of CIROZ's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of CIROZ's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.